All In Biotech

Drug Trial Radar · NCT06979375

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

May 16, 2027

Study completion Jan 23, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

Conditions

  • Heart Failure

Interventions

  • CDR132LDrug

    Administered intravenous infusion of CDR132L once every 4 weeks for 48 weeks.

  • PlaceboDrug

    Administered intravenous infusion of placebo once every 4 weeks for 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Phase: Change in normalised microRNA-132-3p (miR-132)Time frame: From baseline to week 24

Locations

92 sites in 10 countries. Site status is shown where the registry gives one.

  • Concord Repatriation General Hospital - Cardiology Department

    Concord, New South Wales, Australia · Recruiting

  • The Prince Charles Hospital

    Brisbane, Queensland, Australia · Not yet recruiting

  • Royal Adelaide Hospital - Cardiology Department

    Adelaide, South Australia, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Recruiting

  • Victorian Heart Hospital

    Clayton, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital - Cardiology

    Murdoch, Western Australia, Australia · Recruiting

  • Fakultní nemocnice u sv. Anny v Brně

    Brno, Czechia · Completed

  • Nemocnice České Budějovice a.s.

    České Budějovice, Czechia · Recruiting

  • Fakultní Nemocnice Ostrava

    Ostrava-Poruba, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Recruiting

  • Pratia Prague, s.r.o

    Prague, Czechia · Not yet recruiting

  • IKEM

    Prague, Czechia · Recruiting

  • Sana Kliniken Berlin-Brandenburg GmbH - Lichtenberg

    Berlin, Germany · Completed

  • Charité - Campus Benjamin Franklin - Klinik für Kardiologie

    Berlin, Germany · Not yet recruiting

  • Charité - Campus Virchow-Klinikum - Kardiologie, Angiologie und Intensivmedizin (CRU)

    Berlin, Germany · Recruiting

  • Uniklinik TU Dresden - Herzzentrum Dresden GmbH

    Dresden, Germany · Recruiting

  • Universitaetsklinikum Essen - Klinik für Kardiologie und Angiologie

    Essen, Germany · Not yet recruiting

  • Universitätsklinikum Frankfurt aM - Kardiologie

    Frankfurt am Main, Germany · Recruiting

  • Universitätsklinikum Halle - Innere Medizin III

    Halle, Germany · Recruiting

  • Medizinische Hochschule Hannover - Kardiologie und Angiologie

    Hanover, Germany · Recruiting

  • UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie

    Heidelberg, Germany · Recruiting

  • Uniklinik Schleswig-Holstein - Med. Klinik III Kardiologie und Internist. Intensivmedizin

    Kiel, Germany · Recruiting

  • Sir Ganga Ram Hospital-Cardiology

    New Delhi, India · Recruiting

  • Sir Ganga Ram Hospital-Cardiology

    New Delhi, India · Not yet recruiting

  • Rhythm Heart Institute

    Vadodara, Gujarat, India · Recruiting

  • Lisie Hospital

    Kochi, Kerala, India · Recruiting

  • Seth GS Medical College & KEM Hospital

    Mumbai, Maharashtra, India · Recruiting

  • Arneja Heart & Multispeciality Hospital

    Nagpur, Maharashtra, India · Recruiting

  • Arneja Heart & Multispeciality Hospital

    Nagpur, Maharashtra, India · Not yet recruiting

  • G B Pant Institute of Postgraduate Medical Education and Research

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • VMMC & Safdarjung Hospital

    New Dehli, New Delhi, India · Recruiting

  • Dayanand Medical College & Hospital

    Ludhiana, Punjab, India · Recruiting

  • Shri Mahant Indiresh Hospital

    Dehradun, Uttarakhand, India · Recruiting

  • NIPPON MEDICAL SCHOOL HOSPITAL_Cardiovascular medicine

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • JA Shizuoka Kohseiren Enshu Hospital_ Cardiology

    Hamamatsu-shi, Shizuoka, Japan · Not yet recruiting

  • Hyogo Prefectural HarimaHimeji General Medical Center_Cardiology

    Himeji-shi, Hyogo, Japan · Recruiting

  • National Hospital Organization Mito Medical Center_Cardiovascular medicine

    Ibaraki, Japan · Recruiting

  • Yokohama City University Medical Center_Cardiovascular Center

    Kanagawa, Japan · Recruiting

  • Yokohama City University Medical Center_Cardiovascular Center

    Kanagawa, Japan · Not yet recruiting

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.